Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Ocena SPN-812 (kapsułka o przedłużonym uwalnianiu wiloksazyny) u dzieci w wieku przedszkolnym z ADHD

2 października 2026 zaktualizowane przez: Supernus Pharmaceuticals, Inc.

Randomizowane, podwójnie ślepe, wieloośrodkowe, kontrolowane placebo badanie fazy 4 w grupach równoległych dotyczące skuteczności i bezpieczeństwa SPN-812 u dzieci w wieku przedszkolnym (w wieku od 4 do 5 lat) z zespołem nadpobudliwości psychoruchowej z deficytem uwagi (ADHD) )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Przegląd badań

Szczegółowy opis

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

286

Faza

  • Faza 4

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Alabama
      • Saraland, Alabama, Stany Zjednoczone, 36571
    • Arkansas
      • Fayetteville, Arkansas, Stany Zjednoczone, 72703
        • Wycofane
        • Preferred Research Partners-NWA, LLC
      • Little Rock, Arkansas, Stany Zjednoczone, 72211
    • California
      • Anaheim, California, Stany Zjednoczone, 92805
        • Rekrutacyjny
        • Advanced Research Center (ARC), Inc.
        • Kontakt:
      • Encino, California, Stany Zjednoczone, 91316
        • Wycofane
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove, California, Stany Zjednoczone, 92844
        • Zakończony
        • National Institute of Clinical Research (PICR)
      • Imperial, California, Stany Zjednoczone, 92251
      • Long Beach, California, Stany Zjednoczone, 90807
      • Newport Beach, California, Stany Zjednoczone, 92660
        • Wycofane
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial, Colorado, Stany Zjednoczone, 80112
        • Rekrutacyjny
        • IMMUNOe Research Centers
        • Kontakt:
        • Kontakt:
          • Numer telefonu: 303-773-9000
    • Florida
      • Clermont, Florida, Stany Zjednoczone, 34711
        • Wycofane
        • Vertex Clinical Research, LLC
      • Coral Gables, Florida, Stany Zjednoczone, 33134
        • Rekrutacyjny
        • Luna Research Center
        • Kontakt:
          • Numer telefonu: 305-613-7761
      • Gainesville, Florida, Stany Zjednoczone, 32607
        • Zakończony
        • Sarkis Clinical Trials
      • Jacksonville, Florida, Stany Zjednoczone, 32256
        • Rekrutacyjny
        • Clinical Neuroscience Solutions, Inc.
        • Kontakt:
          • Numer telefonu: 904-281-5757
      • Lakeland, Florida, Stany Zjednoczone, 33803
        • Zakończony
        • Accel Research Sites - Lakeland CRU
      • Miami, Florida, Stany Zjednoczone, 33155
      • Orange City, Florida, Stany Zjednoczone, 32763
        • Rekrutacyjny
        • Medical Research Group of Central Florida
        • Kontakt:
          • Numer telefonu: 386-775-7627
      • Orlando, Florida, Stany Zjednoczone, 32801
      • Orlando, Florida, Stany Zjednoczone, 32803
        • Rekrutacyjny
        • APG Research LLC
        • Kontakt:
        • Kontakt:
          • Numer telefonu: 165 407-423-7149
      • Tamarac, Florida, Stany Zjednoczone, 33321
        • Rekrutacyjny
        • D&H Tamarac Research Center
        • Kontakt:
      • Virginia Gardens, Florida, Stany Zjednoczone, 33166
      • Winter Park, Florida, Stany Zjednoczone, 32789
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30328
        • Rekrutacyjny
        • Clinical Integrative Research Center of Atlanta
        • Kontakt:
          • Numer telefonu: 678-705-7341
      • Atlanta, Georgia, Stany Zjednoczone, 30318
      • Decatur, Georgia, Stany Zjednoczone, 30030
        • Rekrutacyjny
        • CenExcel iResearch, LLC
        • Kontakt:
          • Numer telefonu: 404-537-1281
      • Savannah, Georgia, Stany Zjednoczone, 31405
        • Rekrutacyjny
        • CenExel iResearch, LLC.
        • Kontakt:
          • Numer telefonu: 912-744-0800
    • Indiana
      • Evansville, Indiana, Stany Zjednoczone, 47715
        • Zakończony
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown, Kentucky, Stany Zjednoczone, 40004
        • Rekrutacyjny
        • Kentucky Pediatric/Adult Research
        • Kontakt:
      • Owensboro, Kentucky, Stany Zjednoczone, 42301
        • Zakończony
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70115
        • Zakończony
        • DelRicht Research (Touro Medical Center)
      • Prairieville, Louisiana, Stany Zjednoczone, 70769
        • Rekrutacyjny
        • DelRicht Research
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21205
        • Rekrutacyjny
        • Kennedy Krieger Institute
        • Kontakt:
          • Numer telefonu: 443-923-3850
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02445
    • Michigan
      • Bloomfield Hills, Michigan, Stany Zjednoczone, 48302
        • Rekrutacyjny
        • Neurobehavioral Medicine Group
        • Kontakt:
    • Mississippi
      • Flowood, Mississippi, Stany Zjednoczone, 39232
        • Rekrutacyjny
        • Precise Research Centers
        • Kontakt:
          • Numer telefonu: 601-420-5812
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89128
        • Rekrutacyjny
        • Clinical Research of Southern Nevada, LLC.
        • Kontakt:
    • New Jersey
      • Berlin, New Jersey, Stany Zjednoczone, 08009
        • Wycofane
        • Hassman Research Institute
      • Irvington, New Jersey, Stany Zjednoczone, 07111
      • Neptune City, New Jersey, Stany Zjednoczone, 07753
        • Rekrutacyjny
        • Jersey Shore University Medical Center
        • Kontakt:
    • New York
      • New York, New York, Stany Zjednoczone, 10028
        • Wycofane
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham, North Carolina, Stany Zjednoczone, 27705
        • Rekrutacyjny
        • Duke University
        • Kontakt:
          • Numer telefonu: 919-681-1100
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45229
        • Rekrutacyjny
        • Cincinnati Children's Hospital and Medical Center
        • Kontakt:
      • West Chester, Ohio, Stany Zjednoczone, 45069
        • Wycofane
        • CincyScience
    • Oregon
      • Gresham, Oregon, Stany Zjednoczone, 97030
        • Rekrutacyjny
        • Cyn3rgy Research
        • Kontakt:
    • Pennsylvania
      • Hershey, Pennsylvania, Stany Zjednoczone, 17033
        • Rekrutacyjny
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • Kontakt:
        • Kontakt:
          • Numer telefonu: 717-531-5656
    • South Carolina
      • North Charleston, South Carolina, Stany Zjednoczone, 29405
      • Summerville, South Carolina, Stany Zjednoczone, 29486
    • Tennessee
      • Memphis, Tennessee, Stany Zjednoczone, 38119
        • Rekrutacyjny
        • Clinical Neuroscience Solutions, Inc.
        • Kontakt:
          • Numer telefonu: 901-843-1045
    • Texas
      • Bellaire, Texas, Stany Zjednoczone, 77401
        • Wycofane
        • Houston Clinical Trials, LLC.
      • Dallas, Texas, Stany Zjednoczone, 75230
        • Zakończony
        • Javara
      • Plano, Texas, Stany Zjednoczone, 75093
        • Rekrutacyjny
        • AIM Trials, LLC
        • Kontakt:
        • Kontakt:
          • Numer telefonu: 214-856-2778
      • The Woodlands, Texas, Stany Zjednoczone, 77381
    • Virginia
      • Petersburg, Virginia, Stany Zjednoczone, 23805
      • Richmond, Virginia, Stany Zjednoczone, 23220
        • Rekrutacyjny
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • Kontakt:
          • Numer telefonu: 804-628-8736

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

4 lata do 5 lat (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo

Placebo, qd

Placebo will be administered once daily

Eksperymentalny: SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

Inne nazwy:
  • SPN-812

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Ramy czasowe: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Ramy czasowe: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Ramy czasowe: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Ramy czasowe: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Ramy czasowe: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Ramy czasowe: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Ramy czasowe: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Ramy czasowe: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Dyrektor Studium: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

19 marca 2024

Zakończenie podstawowe (Szacowany)

1 stycznia 2028

Ukończenie studiów (Szacowany)

1 stycznia 2028

Daty rejestracji na studia

Pierwszy przesłany

26 lutego 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

1 marca 2021

Pierwszy wysłany (Rzeczywisty)

4 marca 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Inne numery identyfikacyjne badania

  • 812P401

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj